RegeneRx receives notice of allownace from U.S. Patent Office for new indication RegeneRx Biopharmaceuticals has received a Notice of Allowance of a U.S. patent for the use of Thymosin beta 4, certain fragments, isoforms, derivatives and analogues to treat patients with glaucoma and elevated intraocular pressure. Glaucoma refers to a group of eye conditions that lead to damage to the optic nerve. This nerve carries visual information from the eye to the brain. In most cases, damage to the optic nerve is due to increased pressure in the eye, known as intraocular pressure. Glaucoma is the second most common cause of blindness in the United States. The patent will expire in 2026.
RegeneRx receives Israeli acceptance notice for use of TB4 RegeneRx announced that it has received a patent acceptance notice from the Israeli patent office with claims for administering Thymosin beta 4 to prevent or reduce tissue damage caused by an increase in blood flow, as is often the case when cardiac vessels are opened after a blockage causing a heart attack or in similar circumstances when treating stroke victims.